TISIDB

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein.
Domain	PF02931 Neurotransmitter-gated ion-channel ligand binding domain PF02932 Neurotransmitter-gated ion-channel transmembrane region
Function	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

> Gene Ontology [ TOP ]
Biological Process	GO:0001508 action potential GO:0003009 skeletal muscle contraction GO:0003012 muscle system process GO:0006936 muscle contraction GO:0006941 striated muscle contraction GO:0007271 synaptic transmission, cholinergic GO:0007274 neuromuscular synaptic transmission GO:0007517 muscle organ development GO:0007519 skeletal muscle tissue development GO:0007528 neuromuscular junction development GO:0014706 striated muscle tissue development GO:0019226 transmission of nerve impulse GO:0019228 neuronal action potential GO:0035094 response to nicotine GO:0035637 multicellular organismal signaling GO:0042391 regulation of membrane potential GO:0043279 response to alkaloid GO:0046716 muscle cell cellular homeostasis GO:0048630 skeletal muscle tissue growth GO:0050808 synapse organization GO:0050879 multicellular organismal movement GO:0050881 musculoskeletal movement GO:0050905 neuromuscular process GO:0060249 anatomical structure homeostasis GO:0060537 muscle tissue development GO:0060538 skeletal muscle organ development GO:0070050 neuron cellular homeostasis
Molecular Function	GO:0004889 acetylcholine-activated cation-selective channel activity GO:0005216 ion channel activity GO:0005230 extracellular ligand-gated ion channel activity GO:0005231 excitatory extracellular ligand-gated ion channel activity GO:0005261 cation channel activity GO:0015267 channel activity GO:0015276 ligand-gated ion channel activity GO:0015464 acetylcholine receptor activity GO:0022803 passive transmembrane transporter activity GO:0022834 ligand-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0030594 neurotransmitter receptor activity GO:0042165 neurotransmitter binding GO:0042166 acetylcholine binding GO:0070405 ammonium ion binding
Cellular Component	GO:0005892 acetylcholine-gated channel complex GO:0031594 neuromuscular junction GO:0034702 ion channel complex GO:0043235 receptor complex GO:0045211 postsynaptic membrane GO:0097060 synaptic membrane GO:0098794 postsynapse GO:0098802 plasma membrane receptor complex GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04080 Neuroactive ligand-receptor interaction
Reactome	R-HSA-181431: Acetylcholine Binding And Downstream Events R-HSA-629602: Activation of Nicotinic Acetylcholine Receptors R-HSA-629597: Highly calcium permeable nicotinic acetylcholine receptors R-HSA-629594: Highly calcium permeable postsynaptic nicotinic acetylcholine receptors R-HSA-112316: Neuronal System R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell R-HSA-622327: Postsynaptic nicotinic acetylcholine receptors R-HSA-622323: Presynaptic nicotinic acetylcholine receptors R-HSA-112315: Transmission across Chemical Synapses

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04080 Neuroactive ligand-receptor interaction

Reactome

R-HSA-181431: Acetylcholine Binding And Downstream Events
R-HSA-629602: Activation of Nicotinic Acetylcholine Receptors
R-HSA-629597: Highly calcium permeable nicotinic acetylcholine receptors
R-HSA-629594: Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-622327: Postsynaptic nicotinic acetylcholine receptors
R-HSA-622323: Presynaptic nicotinic acetylcholine receptors
R-HSA-112315: Transmission across Chemical Synapses

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CHRNA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CHRNA1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CHRNA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.362	0.659
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.043	0.406
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.111	0.925
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.954	0.277
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.937	0.5
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.972	0.562
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.708	0.446
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.024	0.435
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.538	0.699
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.563	0.463
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.609	0.554
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.779	0.00893

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CHRNA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	4.1	-4.1	0.561
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	5.1	-5.1	0.549
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHRNA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHRNA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHRNA1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHRNA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CHRNA1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CHRNA1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CHRNA1
Name	cholinergic receptor, nicotinic, alpha 1 (muscle)
Aliases	acetylcholine receptor, nicotinic, alpha 1 (muscle); CHRNA; cholinergic receptor, nicotinic, alpha polypepti ......
Chromosomal Location	2q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CHRNA1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CHRNA1.

ID	Name	Drug Type	Targets	#Targets
DB00674	Galantamine	Small Molecule	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA ......	18
DB08838	Agmatine	Small Molecule	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH	7

Browse CHRNA1